Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5‐HT4 receptor agonist, following oral and intravenous administration
- 1 May 1999
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 47 (5) , 483-491
- https://doi.org/10.1046/j.1365-2125.1999.00936.x
Abstract
Aims The purpose of the present study was to assess the pharmacokinetics of the novel selective 5-HT4 receptor agonist SDZ HTF 919 (HTF) including food effect, absolute bioavailability, interoccasion and intersubject variabilities. Methods In the randomized, open-label, three treatment, four period crossover study, HTF was administered to 12 young healthy male subjects as a 12 mg tablet (twice under fasted and once under fed conditions) and a 3 mg intravenous (i.v.) infusion over 40 min (fasted). Pharmacokinetic parameters were obtained by noncompartmental methods. A more comprehensive pharmacokinetic characterization was achieved by integrated modelling of oral (p.o.) and i.v. data. To describe the absorption phase a Weibull function and a classical first order input function were compared. Results Noncompartmental pharmacokinetic analysis revealed a rapid absorption (tmax 1.3 h, fasted), an absolute bioavailability of 11±3%, a biphasic disposition phase with a terminal half-life of 11±5 h, a clearance of 77±15 l h−1, and a volume of distribution at steady state of 368±223 l. The coefficients of interoccasion and interindividual variability in Cmax and AUC ranged between 17 and 28%. Food intake caused a delay (tmax 2.0 h) and decrease in absorption with consequently lower systemic exposure (≈5% absolute bioavailability). Integrated p.o./i.v. pharmacokinetic modelling with a Weibull input function allowed accurate description of individual profiles. Modelling of the data from the p.o. dosing improved the description of the terminal phase by inclusion of the i.v. data and additionally provided quantitative characterization of the absorption phase. Conclusions The pharmacokinetics of HTF could be well described by an integrated modelling approach for both p.o. and i.v. data. The derived model will provide guidance in the design of future studies.Keywords
This publication has 19 references indexed in Scilit:
- First Pharmacokinetic—Pharmacodynamic Study in Humans with a Selective 5‐Hydroxytryptamine4 Receptor AgonistThe Journal of Clinical Pharmacology, 1997
- Leading Article: Central & Peripheral Nervous Systems: 5-Hydroxytryptamine (5-HT)4receptors: physiology, pharmacology and therapeutic potentialExpert Opinion on Investigational Drugs, 1996
- The Serotonin 5-HT4 Receptor. 2. Structure-Activity Studies of the Indole Carbazimidamide Class of AgonistsJournal of Medicinal Chemistry, 1995
- The Serotonin 5-HT4 Receptor. 1. Design of a New Class of Agonists and Receptor Map of the Agonist Recognition SiteJournal of Medicinal Chemistry, 1995
- Review article: 5‐hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implicationsAlimentary Pharmacology & Therapeutics, 1992
- Novel enteric 5-HT receptors and gastrointestinal prokinetic actionPharmacological Research, 1991
- Effects of food on drug absorptionPharmacology & Therapeutics, 1989
- The use of Weibull distribution to describe thein vivo absorption kineticsJournal of Pharmacokinetics and Biopharmaceutics, 1987
- Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equationsJournal of Pharmacokinetics and Biopharmaceutics, 1978
- Linear pharmacokinetic models and vanishing exponential terms: Implications in pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1976